What is the target INR when reversing warfarin in a patient with intracranial hemorrhage?

Target INR for Warfarin Reversal in Intracranial Hemorrhage

The target INR for warfarin reversal in patients with intracranial hemorrhage is <1.4, with a more stringent threshold of <1.2 specifically recommended for intracranial bleeding. 1, 2

Evidence-Based Threshold

The most recent and authoritative guidelines establish clear INR targets:

• For intracranial hemorrhage specifically: INR <1.2 2
• For other severe bleeding: INR <1.4 1

The 2025 French guidelines (most recent) explicitly state that reversal should be initiated when INR >1.2 for intracranial bleeding 2, which is more aggressive than the threshold for other types of severe hemorrhage. This lower threshold for brain bleeds is based on evidence showing that INR values above 1.2 are associated with increased hematoma expansion in intracranial hemorrhage 2.

Rationale for the Lower Threshold in Brain Bleeds

The distinction between 1.2 and 1.4 is clinically meaningful:

• Hematoma expansion risk: Even modest INR elevations (1.2-1.4) correlate with secondary hemorrhage growth in the brain 2
• Mortality impact: Early reversal to INR <1.3 combined with blood pressure control significantly reduces in-hospital mortality 3
• Time-sensitive nature: Brain tissue tolerates ongoing bleeding poorly compared to other anatomical sites

Reversal Protocol

When INR is elevated above these thresholds in the setting of intracranial hemorrhage:

1. Immediate reversal without waiting for INR results if intracranial bleeding is confirmed or strongly suspected 2

2. Administer 4-factor PCC (preferred over 3-factor) plus vitamin K 10 mg IV 1

   • PCC dosing: weight-based according to INR (25-50 IU/kg) 1
   • If INR unavailable: 25 IU/kg as empiric dose 2

3. Recheck INR within 15-60 minutes after PCC administration 1

4. Serial monitoring: Repeat INR at 6-8 hours and 24 hours 1, 2

5. Redose if needed: If INR remains ≥1.4 (or ≥1.2 for intracranial bleeding) at 24-48 hours, give additional vitamin K 10 mg IV 1

Common Pitfalls

• Don't delay reversal waiting for laboratory INR: Point-of-care INR testing is acceptable, and in life-threatening intracranial hemorrhage, empiric reversal should proceed even before INR results 2

• Don't use FFP as first-line: 4-factor PCC achieves faster and more reliable INR correction than fresh frozen plasma 1, 3. FFP should only be used if PCC is unavailable 1

• Don't forget vitamin K: PCC alone provides rapid but temporary reversal; vitamin K (10 mg IV) ensures durable correction 1

• Monitor for INR rebound: The INR can increase again after initial correction, necessitating serial monitoring and potential redosing 1, 2, 1